Results 181 to 190 of about 6,317 (201)

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Respiratory Medicine,the, 2017
Gary T Ferguson, Eugene R Bleecker
exaly  

Benralizumab/vedolizumab

Reactions Weekly, 2023
openaire   +1 more source

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

Drug Safety, 2020
David J Jackson, Sameer K Mathur, Ubaldo J Martin   +2 more
exaly  

Benralizumab/mepolizumab

Reactions Weekly, 2022
openaire   +1 more source

Benralizumab/ciclosporin

Reactions Weekly, 2021
openaire   +1 more source

Benralizumab/Mepolizumab

Reactions Weekly
  +5 more sources

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma

American Journal of Emergency Medicine, 2015
Brian H Rowe
exaly  

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Lancet, The, 2016
Eugene R Bleecker, J Mark Fitzgerald, Alberto A Papi   +2 more
exaly  

Benralizumab/mepolizumab/omalizumab

Reactions Weekly, 2021
openaire   +1 more source

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma

BioMed Research International, 2018
Corrado Pelaia, Cecilia Calabrese, Alessandro Vatrella   +2 more
exaly